FDA advisory committee backs first trastuzumab biosimilar

14-07-2017

The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee has recommended approval of the first biosimilar version of trastuzumab, a breast cancer-fighting monoclonal antibody.


FDA, trastuzumab, biosimilar, Mylan, Biocon, Herceptin, US Food and Drug Ad-ministration, cancer

LSIPR